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Purpose: The aim of this study was to assess the feasibility and efficacy of hypo-
fractionated simultaneous integrated boost-intensity modulated radiotherapy (SIB-
IMRT) using three-layered planning target volumes (PTV) for malignant gliomas. 
Materials and Methods: We conducted a retrospective analysis of 12 patients 
(WHO grade IV-10; III-2) postoperatively treated with SIB-IMRT with concurrent 
temozolomide. Three-layered PTVs were contoured based on gadolinium-en-
hanced magnetic resonance imaging as follows; high risk PTV (H-PTV) as the 
area of surgical bed including residual gross tumor with a 0.5 cm margin; low risk 
PTV (L-PTV) as the area surrounding the high risk PTV with 1.5 cm margin; 
moderate risk PTV (M-PTV) as a line at one-third the distance from high risk PTV 
to low risk PTV. Total dose to high risk PTV was 70 Gy in 8 and 62.5 Gy in 4 pa-
tients. Results: The median follow-up time was 52 months in surviving patients. 
The 2- and 5-year overall survival (OS) rates were 66.6% and 47.6%, respectively. 
The 2- and 5-year progression-free survival (PFS) rates were 57.1% and 45.7%, 
respectively. The median OS and PFS were 48 and 31 months, respectively. Six 
patients (50%) progressed: in-field only in one, out-field or disseminated in 4, and 
both in one patient. All patients completed planned treatments without a toxicity-
related gap. Asymptomatic radiation necrosis was observed in 4 patients at post-ra-
diotherapy 9-31 months. Conclusion: An escalated dose of hypofractionated SIB-
IMRT using three-layered PTVs can be safely performed in patients with 
malignant glioma, and might contribute to better tumor control and survival.
Key Words:   Radiotherapy, intensity-modulated, malignant glioma, hypofraction-
ation, simultaneous integrated boost
INTRODUCTION
Currently, the standard radiotherapy for malignant glioma is to deliver a total of 60 
Gy to the surgical bed or residual tumor with conventional fractionation using 
3-dimensional conformal radiotherapy. However, the majority of tumors recur or 
progress at the primary lesions.1 Although a number of trials have attempted to 
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surgery in principle. 
       
Radiotherapy planning-target definition, dose 
prescription, and normal tissue constraints
Target volume definitions and order of delineation were as 
follows. First, H-PTV was set by drawing a 0.5 cm margin 
to the postoperative surgical margin and the residual gross 
tumor, and then L-PTV was set by expanding the H-PTV 
3-dimensionally to provide a 1.5 cm margin. Lastly, M-
PTV was drawn at the point close to a third of the way to 
H-PTV along the shortest distance between H-PTV and L-
PTV. Organs at risk, such as the eyes, lenses, optic chiasm, 
optic nerves, brain stem, and scalp were also delineated.
In all patients, daily doses of 2.5, 2.15 and 1.8 Gy were 
prescribed to H-PTV, M-PTV and L-PTV, respectively. In 
our institution, two radiation oncologists treated brain tu-
mors, and the dose schemes administered thereby were dif-
ferent between the two. The first scheme was administered 
in 8 patients; 28 fractions of irradiation were administered 
evaluate the benefit of dose escalation, most of them have 
failed to prove a benefit for conventional radiotherapy with 
more than 60 Gy.2-4 Simultaneous integrated boost (SIB)- 
intensity modulated radiotherapy (IMRT) has emerged as a 
novel treatment method and has been shown to provide do-
simetric benefits for protecting adjacent normal tissues.5,6 
Using this method, overall treatment time can be shortened 
and a biologically effective dose (BED) can be escalated by 
hypofractionation, both of which are important for over-
coming radioresistance.7 
At our institution, we have begun to offer hypofractionat-
ed SIB-IMRT as an option to patients with malignant glio-
ma since 2004. Since malignant gliomas typically show a 
gradient of infiltrating tumor cells that decreases as one 
moves away from the mass on microscopy,8,9 we used three-
layered planning target volumes (PTV) to deliver a suffi-
cient dose to the peritumoral area. We conducted this study 
retrospectively to assess the feasibility and efficacy of hy-
pofractionated SIB-IMRT using three-layered PTV for ma-
lignant gliomas.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board 
of our institution (approval number: 4-2012-0938).
Patients and tumor characteristics
This study included 12 patients with histologically confirmed 
malignant gliomas (10 glioblastomas, 2 anaplastic astrocyto-
mas) who were treated by SIB-IMRT postoperatively be-
tween January 2004 and December 2007. All patients pro-
vided informed consent prior to undergoing radiotherapy. 
The median follow-up periods for all the patients and the sur-
viving patients were 36 months (range, 8-65 months) and 52 
months (range, 21-65 months), respectively. Table 1 summa-
rizes their clinical characteristics. The median age of the pa-
tients was 40.5 years (range, 21-70 years). The numbers of 
patients who underwent gross total resection, subtotal resec-
tion and partial resection were nine, two and one, respective-
ly. Retrospective O6-methylguanine-DNA methyltrasferase 
(MGMT) promoter methylation analysis was available in 10 
patients: 8 patients were unmethylated and 2 patients were 
methylated. In all patients, postoperative brain magnetic res-
onance imaging (MRI) was performed within 48 h after sur-
gery to distinguish residual tumor from postoperative 
change. Radiotherapy was begun within 2-3 weeks after 
Table 1. Patient Characteristics (n=12)
Characteristics No. of patients (%)
Age (yrs)
    40.5 (range; 21-70)
Sex
    Male   7 (58)
    Female   5 (42)
Pathology
    Anaplastic astrocytoma   2 (17)
    Glioblastoma 10 (83)
MGMT promoter methylation
    Methylation   2 (17)
    Unmethylation   8 (66)
    Unevaluable   2 (17)
Multiplicity at presentation
    Solitary 11 (92)
    Multiple   1 (8)
Karnofsky performance status (%)
    100   1 (8)
    90   7 (58)
    80   3 (25)
    50   1 (8)
Extent of Surgery
    Grossly total resection   9 (75)
    Subtotal resection   2 (17)
    Partial resection   1 (8)
Chemotherapy
    Temozolomide+lomustine   1 (8)
    Temozolomide alone 11 (92)
MGMT, O6-methylguanine-DNA methyltrasferase.
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Toxicity assessment and follow-up
Toxicity was graded according to the toxicity criteria of the 
Radiation Therapy Oncology Group/European Organization 
for Research and Treatment of Cancer. In all patients, com-
plete blood cell counts were taken weekly during radiother-
apy. MRI was obtained 4 weeks after the completion of ra-
diotherapy and every 3 to 4 months thereafter to check for 
progression. In-field progression was defined as recurrence 
within the target volumes. Out-field recurrence was defined 
as recurrence outside of the L-PTV. Dissemination was de-
fined as recurrence of multiple foci outside the target vol-
ume, including leptomeningeal seeding. In cases of patients 
who underwent total removal of a tumor, recurrence was 
regarded as progression. Pseudoprogression was defined as 
a transient increase in contrast enhancement within the radi-
ation field, detected before 3 months post-radiotherapy and 
resolving or stabilizing after 1-2 months. 
Progression-free survival (PFS) and overall survival (OS) 
were calculated from the day of surgery and estimated by 
the Kaplan-Meier method. The significance of prognostic 
factors was analyzed by the log-rank test. 
 
RESULTS
 
Treatment-related toxicity
Hematologic toxicities during the treatment period included 
the following: grade I anemia in 2, grade II anemia in one, 
grade II thrombocytopenia in 2, and grade III neutropenia 
in 2 patients. Grade I central nervous system toxicity was 
observed in 2 patients and grade II in 3 patients. Four pa-
tients experienced decreased appetite. Three patients showed 
pseudoprogression. Radiation necrosis (RN) occurred in 4 
patients at post-radiotherapy 9, 11, 14 and 31 months with-
out any symptom. Fig. 1 demonstrates the serial MRI and 
helical tomotherapy plan of a patient with RN detected at 
post-radiotherapy 11 months. Intracranial hemorrhage de-
veloped in one patient at post-radiotherapy 4 years with 
sudden signs of increased intracranial pressure (IICP), 
while the correlation between this and radiotherapy was un-
clear. The patient recovered after surgical removal of the 
hematoma.
Survivals and prognostic factors
The median follow-up periods for all of the patients and the 
surviving patients were 28 months (range 10-65 months) 
and 52 months (range 21-65), respectively. The 2-, 3- and 
at the total doses of 70 Gy, 62 Gy and 50.4 Gy, respectively. 
The other schedule was performed in 4 patients; irradiation 
was performed 25 times with the total doses of 62.5 Gy, 
53.8 Gy and 45 Gy, respectively. When the total prescribed 
doses were converted to a BED with α/β ratio=3, 8 patients 
(67%) received ≥125 BEDGy3 and the remaining 4 (33%) 
patients received 114.6 BEDGy3. Post-operative radiothera-
py was initiated 14-39 days (median 16 days) after surgery. 
The start of radiotherapy was delayed in 2 patients, who were 
operated on at another hospital and referred to our hospital 
for radiotherapy. Median overall treatment time was 40.5 
days (range, 37-51 days). The treatment period exceeded 6 
weeks in 4 patients because of failure with medical equip-
ment in 2 patients, leukocytopenia in one patient, and a 
poor general condition in one patient. Two patients under-
went linac-based IMRT, and 9 underwent helical tomother-
apy. Linac-based IMRT was planned with the Corvus® 
(Nomos Corp., Pittsburg, PA, USA) system, and helical to-
motherapy with the Hi-Art® (Tomotherapy Inc., Madison, 
WI, USA) planning station. 
Comparative planning analysis
We performed a comparative planning study in order to de-
termine the dosimetric benefits of a three-layered target vol-
ume plan (3LP), compared to a simple two-layered target 
volume plan (2LP) in terms of accounting for gradual de-
creases of invasion into surrounding normal brain tissue by 
glioma cells. 3LP was eventually applied to the patients. In 
2LP, M-PTV was removed from prescriptions while main-
taining the same prescription and dose constraints for other 
PTVs and normal tissues for rational comparison. We as-
sumed that all of the 12 patients were prescribed 70 Gy, 60.2 
Gy and 50.4 Gy with 28 fractions for H, M and L-PTV, re-
spectively, although 4 of the 12 patients actually received 25 
fractions. The results of the two plans were compared via a 
radiation dose profile, differential dose volume histogram 
(DVH), and 3D-dose distribution using Mathmatica® (Wol-
fram Research, Champaign, IL, USA). 
Chemotherapy
All of the patients received temozolomide (TMZ)-based 
chemotherapy, which was administered concurrently with 
radiotherapy in 11 of the 12 patients and sequentially after 
radiotherapy in 1 patient. The drug was administered at 75 
mg/m2 daily during radiotherapy, and 150-200 mg/m2 daily 
after radiotherapy. The cyclic administration of TMZ was 
performed for 4-24 cycles (median 11.5 cycles).
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Significant prognostic factors shown to be related to bet-
ter OS on univariate analysis included Karnofsky perfor-
mance status (KPS) 90 or 100 (p=0.005) and a total dose 
≥125 BEDGy3 (p=0.032). All patients with MGMT meth-
ylation were alive, but the difference in OS was not signifi-
cant (p=0.167). Patients without pseudoprogression (p= 
0.237) and with radiation necrosis (p=0.220) tended to 
show better OS. For PFS, KPS 90 or 100 (p=0.037) and 
without pseudoprogression (p=0.025) were shown to be 
significant factors on univariate analysis. Patients who re-
ceived a total dose ≥125 BEDGy3 (p=0.094) and with radia-
tion necrosis (p=0.189) tended to exhibit better PFS, but 
these were not statistically significant (Table 2). 
5-year OS rates were 66.6%, 57.1% and 47.6%, respective-
ly. The 2-, 3- and 5-year PFS rates were 57.1%, 45.7% and 
45.7%, respectively (Fig. 2). The median OS was 48 
months (95% CI: 29-67 months). Six patients experienced 
progression, and the median PFS was 32 months. Five of 
the six patients with progression died of the disease. The 
other patient, who is still alive, experienced tumor recur-
rence as leptomeningeal seeding at post-radiotherapy 21 
months and received craniospinal irradiation and TMZ-
based salvage treatment. Five of the six patients without 
progression have remained in a disease-free state up to the 
last follow-up, while the other patient died of acute pneu-
monia. 
Fig. 1. A patient who experienced non-symptomatic radiation necrosis 11 months after treatment. He underwent near total tumor removal 
and helical tomotherapy based on the three-layered target volumes with dose prescriptions of 70 Gy, 60.2 Gy, and 50 Gy. He is alive after 
more than 5 years without evidence of disease progression. RT, radiotherapy.
Fig. 2. Survival curves. (A) Overall survival. (B) Progression-free survival.
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21 months after treatment of a tumor of left temporal ori-
gin. The other patient died at 15 months of in-field failure 
that occurred in H-PTV at post-RT 8 months. 
Effect of three-layered target volumes: comparative 
planning study with two-layered target volume
Fig. 3 shows the 3D dose distribution of the target volumes 
and dose profiles on the axial plane for one representative 
patient. The decrease in dose from the margin of H-PTV to 
L-PTV was much slower in 3LP than in 2LP, in which the 
dose decreased sharply as soon as it passed out of H-TPV. 
Between the two planning methods, differential DVHs were 
similar for H-PTV, but clearly different for M-PTV and L-
PTV. While L-PTV in 2LP had a sharp peak at 50.4 Gy, that 
in 3LP showed a gentle slope, suggesting a gradual de-
crease of radiation dose from the border of H-PTV to L-
PTV. In 3LP and 2LP for the 15 patients, the D95% of H-
PTV were 69.7±0.5 Gy and 69.6±0.6 Gy, respectively, and 
those of L-PTV were 52.1±1.1 Gy and 50.0±0.8 Gy, respec-
tively, showing little difference between the two plans; how-
Patterns of failure
In total, six cases of progression were noted. One was in-field 
(in H-PTV), one was in-field (in L-PTV) with dissemination, 
one was out-field, one was out-field with dissemination, and 
two involved dissemination. 
Of the 8 patients prescribed at 70 Gy (BED 128 Gy3), 
there were no in-field failures, but out-field failures were 
observed in 3 patients. The failure patterns were as follows: 
skin recurrence caused by histologically confirmed surgical 
seeding; multifocal recurrence occurred out-field of the ip-
silateral and contra-lateral brain with leptomeningeal seed-
ing; and out-field recurrence followed by disseminated dis-
ease. On the contrary, for the 4 patients prescribed at 62.5 
Gy (BED 114 Gy3), recurrence occurred in 3 patients. One 
patient among them experienced in-field failure at the L-
PTV 12 months after radiotherapy with concomitant lepto-
meningeal seeding. The extent of disease was very wide 
and tumor invaded the optic chiasm. In another patient, lep-
tomeningeal seeding occurred in the lateral ventricle out-
side the radiotherapy (RT) field and in the parietal area at 
Table 2. Univariate Analysis of 3-Year OS and PFS Rate
Case (n)
3-yr OS 3-yr PFS
% p value % p value
Karnofsky performance status (%) 0.005 0.037
    90-100   8 87.5 60
    <90   4   0 25
Extent of resection 0.559 0.393
    Total   9 66.7 48.6
    Subtotal or partial   3 33.3 33.3
Pathology 0.82 0.998
    Anaplastic astrocytoma   2 50 50
    Glioblastoma 10 60 43.8
Multiplicity 0.491 0.146
    Yes   1   0   0
    No 11 63.6 49.9
MGMT status 0.167 0.131
    Methylated   2 100 100
    Unmethylated   8 50 23.4
Total dose 0.032 0.094
    ≥125 BEDGy3   8 75 60
    <125 BEDGy3   4 25   0
Pseudoprogression 0.237 0.025
    Yes   3 33.3   0
    No   9 64.8 64.8
Radiation necrosis 0.22 0.189
    Yes   4 75 75
    No   8 46.9 23.4
OS, overall survival; PFS, progression-free survival; BED, biologically effective dose; MGMT, O6-methylguanine-DNA methyltrasferase.
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optimal fractionation should go beyond the fraction size of 
1.8-2.0 Gy. In a previous study by the Narayana group,13 
who used IMRT of conventional fractionation, 95% of re-
lapses were still local. In our study, there was no in-field 
failure among patients whose H-PTV was irradiated at 70 
Gy (BED 128 Gy3) with 2.5 Gy per fraction. We used 2.5 
Gy rather than a larger fraction size in order to reduce the 
risk of complications and to maximize the benefits of frac-
tionation through a treatment period of around 5 weeks. In 
the cases of the IMRT trial by Floyd, et al.14 that prescribed a 
total dose of 50 Gy (133 BEDGy3) with 5 Gy per fraction 
and the trial by Iuchi, et al.15 that prescribed a total dose of 
48-68 Gy (260 BEDGy3) with 6-8.5 Gy per fraction, the in-
cidences of RN requiring surgical intervention were 15% (3 
of 20 patients) and 12% (3 of 25 patients), respectively. In 
our study, 4 of 12 patients (33%) experienced RN. They 
were all asymptomatic and the necrosis occurred mostly near 
the H-PTV area. One possible reason for this relatively high 
incidence of RN is the concurrent use of TMZ. Since both 
the first and the 5-year follow-up report of concurrent TMZ 
and conventional RT16,17 and a single institutional experience 
of hypofractionated RT with concurrent TMZ did not men-
tion RN specifically,18 little is known about the incidence of 
RN after concurrent TMZ and hypofractionated RT. De-
ever, those of M-PTV were 60.3±1.9 Gy and 54.9±1.7 Gy, 
respectively, showing a dose increase of around 6 Gy 
(10%) in 3LP. The D95% of M-PTV in 3LP was close to 
the dose prescribed for M-PTV of the three-layered target. 
V60 Gy and V50 Gy were about 22% and 37% higher, re-
spectively, in 3LP than in 2LP. However, the difference in 
dose distribution for surrounding normal tissues between 
the two plans was less than 3%, a negligible level.
DISCUSSION
Malignant glioma is known to involve a dismal prognosis 
despite the availability of multi-modality approaches of sur-
gery, radiotherapy and TMZ-based chemotherapy.10 This 
study reports promising preliminary treatment outcomes 
and relatively high incidence of RN after SIB-IMRT using 
three-layered target volumes.  
In this study, we applied an intermediate hypofraction-
ation scheme (2.5 Gy per fraction to high-risk area) instead 
of the conventional fractionation. Since glioblastoma cells 
exhibit a low ratio on in vitro survival curves11 and all radi-
ation dose escalations up to 90 Gy with conventional frac-
tionation develop in-field recurrence,12 we hypothesized that 
Fig. 3. Comparative planning study between three- (3LP) and two-layered plans (2LP). (A and B) Three-dimensional dose distributions in 3LP and 2LP. (C) A 
coronal two-dimensional dose distribution along the red line in three-dimensional dose distribution. Points a and b mark the outer margins of H-PTV and 
L-PTV, respectively. The elliptical purple area from points a to b shows the area of key dose differences between 3LP and 2LP. (D) Differential dose volume 
histogram for H, M, L-PTVs in two plans. PTV, planning target volumes.
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chemotherapy. This suggests that if local control and survival 
are improved, a risk of dissemination may increase.
Since this report is a single institutional, retrospective 
study of small number of patients, the result of our study is 
hard to be generalized to all malignant glioma patients. In ad-
dition, our study is a preliminary report of single treatment 
technique and not a comparison study, therefore, it is difficult 
to draw a conclusion involving superiority of the technique. 
Despite such limitations, the encouraging outcomes in this 
report warrant further investigation and future clinical stud-
ies of IMRT for malignant gliomas. 
In summary, hypofractionated SIB-IMRT for malignant 
glioma seems to be tolerable and improving local control in 
patients who underwent resection. Since the incidence of 
RN is relatively high in these patients with concurrent TMZ, 
this technique might be safer and helpful for the patients 
with contraindications for TMZ.  
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